title: Magnesium sulphate therapy in women with pre-eclampsia and eclampsia in Kuwait.
abstract: OBJECTIVE
  To evaluate the outcome of the use of MgSO4 therapy in women with severe pre-eclampsia in Kuwait from January 2002 to December 2004.
  
  
  METHODS
  The study involved 450 women managed at the Maternity Hospital in Kuwait with a blood pressure of 160/110 mm Hg and proteinuria of >0.3-5 g/24 h. A loading dose of 4 g MgSO4 was administered intravenously over 20 min and then the maintenance dose continued at 1 g/h for 24 h postpartum. Magnesium sulphate toxicity was monitored by urine output, deep tendon reflexes and serum magnesium levels and managed with an infusion of 10 ml of 10% calcium gluconate and cessation of magnesium infusion. Adjunct therapy included intravenous hydralazine 10 mg and labetalol 100 mg. The mode of delivery was determined after stabilizing the patient.
  
  
  RESULTS
  The women included Kuwaitis (n = 200, 44.4%), Asians (n = 129, 28.7%) and other Arabs (n = 116, 25.8%) with a mean age of 29.7 +/- 6.7 years (primigravida: n = 233, 51.8%; other parities: n = 217, 48.2%). Antenatal complications included intra-uterine growth restriction (n = 136, 30.2%), oliguria (n = 39, 8.7%), haemolysis, elevated liver enzymes and low platelet count syndrome (n = 30, 6.6%), abruptio placentae (n = 20, 4.4%), eclampsia (n = 15, 3.3%), and preterm birth (n = 253, 55.2%). Caesarean section (n = 241, 53.6%) was the main mode of delivery. The perinatal mortality rate was 27 per 1,000. Magnesium sulphate toxicity observed as reduced tendon reflexes occurred in 14 (3.1%) patients and flushing, nausea and vomiting and blocked nostrils in 86 (19.1%). There was no association between adverse outcomes and maternal serum magnesium concentrations and no maternal mortality occurred.
  
  
  CONCLUSIONS
  Magnesium sulphate was effective in preventing recurrence of eclamptic fits and safe for both mother and fetus.
authors.affiliation: Department of Obstetrics and Gynaecology, Faculty of Medicine, Kuwait University, Kuwait. Omu@hsc.edu.kw
authors.forename: A E
authors.initials: AE
authors.lastname: Omu
authors.forename: J
authors.initials: J
authors.lastname: Al-Harmi
authors.forename: H L
authors.initials: HL
authors.lastname: Vedi
authors.forename: L
authors.initials: L
authors.lastname: Mlechkova
authors.forename: A F
authors.initials: AF
authors.lastname: Sayed
authors.forename: N S
authors.initials: NS
authors.lastname: Al-Ragum
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004461:Eclampsia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007730:Kuwait; D007741:Labetalol / Q000627:therapeutic use; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011446:Prospective Studies; D012307:Risk Factors; D015149:Tocolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D015149:Tocolytic Agents; D006830:Hydralazine; D008278:Magnesium Sulfate; D007741:Labetalol